Press Releases November 5, 2024: MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes MaaT Pharma Provides Third Quarter 2024 Business and Financial Results and Announces Management Changes Completion…MaaT PharmaNovember 5, 2024
Press Releases October 15, 2024: MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute Graft-versus-Host Disease MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…MaaT PharmaOctober 15, 2024
Press Releases September 19, 2024: MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update Positive…MaaT PharmaSeptember 19, 2024
Press Releases September 9, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…MaaT PharmaSeptember 9, 2024
Press Releases September 4, 2024: MaaT Pharma To Present and Participate in Investor and Medical Conferences in September MaaT Pharma To Present and Participate in Investor and Medical Conferences in September Lyon, France,…MaaT PharmaSeptember 4, 2024
Press Releases August 9, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…MaaT PharmaAugust 9, 2024
Press Releases July 5, 2024: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…MaaT PharmaJuly 5, 2024
Press Releases July 5, 2024: MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract…MaaT PharmaJuly 5, 2024
Press Releases July 2, 2024: MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033…MaaT PharmaJuly 2, 2024
Press Releases June 25, 2024: MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating and a Target Price of EUR 16 MaaT Pharma Announces Initiation of Coverage of its Stock by Stifel with a Buy Rating…MaaT PharmaJune 25, 2024